Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

ABC News' Dr. Tara Narula breaks down the FDA's decision to stop the making of compound versions of weight loss medications.

Increasing access to these effective evidence-based treatments would benefit our society as a whole, not just those impacted ...

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

Physicians need to meet patients ‘where they are’ to develop a comprehensive plan to keep weight off and live a healthy ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study sugges ...

GLP-1 agonists, also known as incretin mimetics, are a class of medication that is primarily used to treat type 2 diabetes and, in some cases, obesity. "The glucagon-like peptide (GLP-1 ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Drugs like Ozempic have a positive impact on weight loss, though only for a short period, with long-term health implications ...